文献速递细菌感染、耐药与抗菌药物

德国2015至2018年幽门螺杆菌抗菌药物耐药性

Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018.
PubMed 文献 · Clin Microbiol Infect · 2019-06-15

该研究采用分子遗传学方法检测1851例未治疗幽门螺杆菌阳性患者的胃组织样本,评估对克拉霉素、左氧氟沙星和四环素的原发性耐药。结果显示克拉霉素耐药率为11.3%,左氧氟沙星为13.4%,四环素为2.5%。女性及既往因无关细菌感染使用抗菌药物是克拉霉素耐药的危险因素,高龄与左氧氟沙星耐药相关。

要点

  • 未治疗患者中克拉霉素原发耐药率为11.3%,仍可考虑作为一线经验性治疗。
  • 左氧氟沙星原发耐药率达13.4%,高龄(≥65岁)者耐药风险显著增高。
  • 四环素耐药率低(2.5%),但近十分之一患者可能携带克拉霉素耐药菌株。

核心结论

  • 在未治疗患者中克拉霉素仍可推荐用于一线根除治疗,但鉴于近十分之一患者可能携带克拉霉素耐药菌株,建议治疗前进行药敏试验或选择替代疗法。

研究设计与样本

  • 研究纳入1851例未经治疗的幽门螺杆菌阳性患者的胃组织样本,采用实时PCR或PCR结合Sanger测序检测克拉霉素、左氧氟沙星和四环素耐药相关突变,并进行单变量和多变量逻辑回归分析。

主要发现

  • 总体原发耐药率:克拉霉素11.3%(210/1851),左氧氟沙星13.4%(201/1497),四环素2.5%(38/1497),克拉霉素/左氧氟沙星联合耐药率为2.6%(39/1497)。
  • 女性(aOR 2.3,95% CI 1.6-3.4)和既往因无关细菌感染使用抗菌药物(aOR 2.6,95% CI 1.5-4.5)是克拉霉素耐药的危险因素。
  • 年龄≥65岁 compared with 18-35岁与左氧氟沙星耐药相关(aOR 6.6,95% CI 3.1-14.2)。

临床怎么用

  • 对于未治疗患者,可考虑克拉霉素经验性一线根除治疗,但需警惕约11.3%的原发耐药率。
  • 建议治疗前进行药敏试验或选择替代疗法,尤其对于女性或有既往抗菌药物使用史的患者。
  • 对于高龄(≥65岁)患者,应关注左氧氟沙星耐药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: National and international guidelines recommend empiric first-line treatments of individuals infected with Helicobacter pylori without prior antimicrobial susceptibility testing. For this reason, knowledge of primary resistance to first-line antibiotics such as clarithromycin is essential. We assessed the primary resistance of H. pylori in Germany to key antibiotics by molecular genetic methods and evaluated risk factors for the development of resistance. METHODS: Gastric tissue samples of 1851 yet treatment-naïve H. pylori-positive patients were examined with real-time PCR or PCR and Sanger sequencing for mutations conferring resistance to clarithromycin, levofloxacin and tetracycline. Clinical and epidemiological data were documented and univariable and multivariable logistic regression analyses were conducted. RESULTS: Overall primary resistances were 11.3% (210/1851) to clarithromycin, and 13.4% (201/1497) to levofloxacin; resistance to tetracycline (2.5%, 38/1497) was as low as combined resistance to clarithromycin/levofloxacin (2.6%, 39/1497). Female sex and prior antimicrobial therapies owing to unrelated bacterial infections were risk factors for clarithromycin resistance (adjusted OR (aOR) 2.3, 95% CI 1.6-3.4; and 2.6, 95% CI 1.5-4.5, respectively); older age was associated with levofloxacin resistance (aOR for those ≥65 years compared with those 18-35 years: 6.6, 95% CI 3.1-14.2). CONCLUSIONS: Clarithromycin might still be recommended in first-line eradication therapies in yet untreated patients, but as nearly every tenth patient may carry clarithromycin-resistant H. pylori it may be advisable to rule out resistance ahead of treatment by carrying out susceptibility testing or prescribing an alternative therapy.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Bluemel B, Goelz H, Goldmann B, et al. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect. 2019. PMID: 31212078. doi:10.1016/j.cmi.2019.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。